615 Antisense oligonucleotide-based drug development for people with cystic fibrosis carrying the 2789+5 G-to-A splicing mutation

Autor: Y. Oren, O. Avizur Barchad, E. Ozeri Galai, R. Elgrabli, T. Mordechai, T. Blinder, N. Stanleigh, E. Kerem, B. Kerem

Publikováno v: Journal of Cystic Fibrosis. 21:S340-S341

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86c95098633bc88d7d10a0b5e6f5edff
https://doi.org/10.1016/s1569-1993(22)01305-4

619 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis therapeutic approach for the W1282X nonsense mutation

Autor: O. Avizur Barchad, Y. Oren, E. Ozeri Galai, R. Elgrabli, M. Schirelman, T. Blinder, C. Stampfer, M. Ordan, O. Laselvab, M. Cohen Cymberknoh, E. Kerem, C. Bear, B. Kerem

Publikováno v: Journal of Cystic Fibrosis. 21:S342

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a92a95ca0449a1601697b0b10f1b5fa8
https://doi.org/10.1016/s1569-1993(22)01309-1

P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation

Autor: Y.S. Oren, O. Avizur Barchad, E. Ozeri Galai, R. Elgrabli, T. Mordechai, T. Blinder, N. Stanleigh, E. Kerem, B. Kerem

Publikováno v: Journal of Cystic Fibrosis. 21:S68

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42f48fecf8110950b48c396e67ad379d
https://doi.org/10.1016/s1569-1993(22)00362-9

Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.

Autor: Oren YS; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Avizur-Barchad O; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Ozeri-Galai E; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Elgrabli R; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Schirelman MR; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Blinder T; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Stampfer CD; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Ordan M; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel., Laselva O; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; Division of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada., Cohen-Cymberknoh M; Pediatric Pulmonology Unit and CF Center, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel., Kerem E; CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel., Bear CE; Division of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada., Kerem B; SpliSense Biohouse Labs, Hadassah Ein Kerem, Jerusalem, Israel; Department of Genetics, The Hebrew University, Jerusalem, Israel. Electronic address: batshevak@savion.huji.ac.il.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2022 Jul; Vol. 21 (4), pp. 630-636. Date of Electronic Publication: 2021 Dec 28.

The Class II cavity preparation in primary molars, a survey of the literature.

Autor: Blinder T

Publikováno v: The Journal of the New Jersey State Dental Society [J N J State Dent Soc] 1968 Jan; Vol. 39 (5), pp. 196-206 passim.